Showing results (21-30 of 44) with videos related to
Sort By:
Pageof 5
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.BMC Cancer|October 9, 2012
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testRalf Kronenwett, Kerstin Bohmann, Judith Prinzler, et al.Oncoimmunology|October 3, 2024
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinomaIsis Lozzi, Alexander Arnold, Matthias Barone, et al.Journal of Proteome Research|November 11, 2011
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profilingScarlet F Brockmöller, Elmar Bucher, Berit M Müller, et al.Neoplasia (New York, N.Y.)|September 13, 2023
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancerInga Hoffmann, Mihnea P Dragomir, Nanna Monjé, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian CancerSofya Marchenko, Niklas Goernitz, Wiebke Alina Zoern, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX TrialTheresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 yearsBerit M Pfitzner, Bianca Lederer, Judith Lindner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.Pageof 5